While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance. Investors looking beyond large-cap names may find compelling opportunities in mid-cap stocks that deliver strong growth and defy broader market weakness.
Here are three mid-cap medical stocks that have significantly outperformed the broader market so far this year. Each shows strong momentum, bullish analyst sentiment, and potential for continued upside.
